- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06751238
Studie for å evaluere farmakokinetikken (PK), sikkerhet og tolerabilitet opp til 6 år med intravenøs (i.v.) Secukinumab hos pediatriske deltakere med juvenil psoriasisartritt (JPsA).
En åpen, multisenterstudie for å evaluere farmakokinetikk, sikkerhet og tolerabilitet opp til 6 år med intravenøs Secukinumab-infusjoner hos pediatriske deltakere med juvenil psoriasisartritt
The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a multicenter, open-label study with an optional treatment extension period to evaluate pharmacokinetics, safety and tolerability (up to 6 years) of i.v. secukinumab in pediatric patients with JPsA.
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-post: novartis.email@novartis.com
Studer Kontakt Backup
- Navn: Novartis Pharmaceuticals
Studiesteder
-
-
California
-
Loma Linda, California, Forente stater, 92354
- Rekruttering
- Loma Linda University Health
-
Ta kontakt med:
- Monica Pizana
- Telefonnummer: +1 909 558 5830
- E-post: mpizana@llu.edu
-
Hovedetterforsker:
- Wendy De La Pena
-
-
Florida
-
Gainesville, Florida, Forente stater, 32610-8068
- Rekruttering
- University of Florida
-
Hovedetterforsker:
- Christian Oliveros
-
Ta kontakt med:
- Joel Ravel
- E-post: Joal.Ravel@UFHelath.ORG
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Ann and Robert H Lurie Childs Hosp
-
Hovedetterforsker:
- Pooja Patel
-
Ta kontakt med:
- Tyler Sorensen
- Telefonnummer: +1 312 227 4811
- E-post: tsorensen@luriechildrens.org
-
-
New York
-
New York, New York, Forente stater, 10032
- Rekruttering
- Col Uni Med Center New York Presby
-
Ta kontakt med:
- Marcela Arizabaleta
- Telefonnummer: +1 646 317 1669
- E-post: ma5005@cumc.columbia.edu
-
Hovedetterforsker:
- Lisa Imundo
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28203
- Rekruttering
- Levine Childrens Hospital
-
Hovedetterforsker:
- Sheetal Vora
-
Ta kontakt med:
- Haley D Furr
- Telefonnummer: +1 800 821 1535
- E-post: Haley.Furr@advocatehealth.org
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Rekruttering
- Cincinnati Childrens Hospital
-
Hovedetterforsker:
- Hermine Brunner
-
Ta kontakt med:
- Megan Quinlan-Waters
- Telefonnummer: +1 513 636 7261
- E-post: Megan.Quinlan-Waters@cchmc.org
-
Cleveland, Ohio, Forente stater, 44106-5028
- Rekruttering
- Univ Hosp Cleveland Medical Center
-
Hovedetterforsker:
- Ezequiel Borgia
-
Ta kontakt med:
- Katrina Gogin
- Telefonnummer: +1 216 844 7164
- E-post: katrina.gogin@uhhospitals.org
-
-
Oregon
-
Portland, Oregon, Forente stater, 97232
- Rekruttering
- Legacy Emanuel Research Hosp Portland
-
Hovedetterforsker:
- Daniel Joseph Kingsbury
-
Ta kontakt med:
- Brenna Bogle
- Telefonnummer: +1 503 413 5447
- E-post: bbogle@lhs.org
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Rekruttering
- Childrens Hosp Pittsburgh UPMC
-
Hovedetterforsker:
- Margalit Rosenkranz
-
Ta kontakt med:
- Vibha Chauhan
- Telefonnummer: +1 412 692 6327
- E-post: vibha.chauhan@chp.edu
-
-
Texas
-
El Paso, Texas, Forente stater, 79902
- Rekruttering
- Texas Arthritis Center
-
Hovedetterforsker:
- Sanjay Chabra
-
Ta kontakt med:
- Jose Cos
- E-post: j.cos@aara.care
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84113
- Rekruttering
- University of Utah
-
Ta kontakt med:
- Tressie Rollins
- Telefonnummer: +1 415 515 8212
- E-post: tressie.rollins@hsc.utah.edu
-
Hovedetterforsker:
- Peter Chiraseveenuprapund
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
Participants parent's or legal representative(s) written informed consent and child's assent, if appropriate, must be obtained before any study related activity or assessment is performed. Of note, if the participant reaches age of consent (as per local law) during the study, they will also need to sign the corresponding study ICF (Informed Consent Form).
-
Males and females ≥2 years old to <18 years old at the time of screening.
-
Confirmed diagnosis of JPsA according to the modified International League of Associations for Rheumatology (ILAR) classification criteria that must have occurred at least 6 months prior to screening.
-
Active JPsA disease defined as ≥3 active joints (swollen or if not swollen must be both tender and limited range of motion) at baseline (BSL).
-
Inadequate response (≥1 month) or intolerance to ≥1 Non-Steroidal Anti-Inflammatory Drug (NSAID) at screening.
-
Inadequate response (≥2 months) or intolerance to ≥ 1 Disease Modifying Anti-Rheumatic Drug (DMARD) at screening.
-
Concomitant use of the following second-line agents such as disease-modifying and/or immunosuppressive drugs to treat the JPsA will be allowed:
- Stable dose of methotrexate (MTX) (maximum of 20 mg/ m2 BSA/ week) for at least 4 weeks prior to the BSL visit, with folic/folinic acid supplementation (according to standard medical practice of the center).
- Stable dose of an oral corticosteroid (CS) at a prednisone equivalent dose of <0.2 mg/kg/day or up to 10 mg/day maximum, whichever is less, for at least 7 days prior to BSL.
- Stable dose of no more than one NSAID for at least 1 week prior to BSL.
Key Exclusion Criteria:
- Participants with body weight less than 10 kg at screening.
- Use of other investigational drugs within 4 weeks or 5 half-lives of BSL, or until the expected pharmacodynamic effect has returned to BSL, whichever is longer.
- History of hypersensitivity to study drug or its excipients or to drugs of similar chemical classes.
- Participants with active inflammatory bowel disease or active uveitis at screening or BSL.
- Fulfilling diagnostic criteria for any International League of Associations for Rheumatology (ILAR ) juvenile idiopathic arthritis (JIA) category other than JPsA at BSL.
- Participants treated with prohibited medication
- Participants taking any non-biologic DMARD at screening except for MTX.
- Any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
Other inclusion/exclusion criteria may apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Secukinumab
Secukinumab administered intravenously in pediatric participants with JPsA |
Intravenous secukinumab
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum concentration on Day 1
Tidsramme: Pre-infusion and end of infusion (EOI) at Day 1
|
Maximum concentration of secukinumab on Day 1 |
Pre-infusion and end of infusion (EOI) at Day 1
|
|
Maximum concentration at steady-state (Cmax, ss)
Tidsramme: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
|
Maximum concentration at steady-state. |
Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
|
|
Minimum concentration at steady-state (Cmin, ss)
Tidsramme: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
|
Minimum concentration at steady-state |
Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
|
|
Area under the concentration-time curve at steady-state (AUCtau, ss)
Tidsramme: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
|
Area under the concentration-time curve at steady-state during a dosing interval |
Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
|
|
Average concentration at steady-state (Cavg,ss)
Tidsramme: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
|
Average concentration at steady-state |
Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to Week 20
|
Number of participants with AEs and SAEs as a measure of safety and tolerability |
Up to Week 20
|
|
Number of participants with clinically significant changes in clinical laboratory measures and vital signs.
Tidsramme: Up to Week 20
|
Number of participants with clinically significant changes in clinical laboratory measures and vital signs as a measure of safety and tolerability |
Up to Week 20
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CAIN457G22101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .